2127387-94-2
2127387-94-2
Chemical Structure
BGT-002
Synonym(s): 326E
- CAS No.: 2127387-94-2
- Formula:C19H34O4
- Molecular Weight:326.47
InChIKey: UUPWWWGROSGLPP-AATRIKPKSA-N
SMILES: CC(CCCC/C=C/CCCCCC(C)(C(O)=O)C)(C(O)=O)C
Biological Activity: BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BGT-002 | 99.35% | BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Xie Z, et al. The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. Cell Metab. 2025 Nov 4;37(11):2149-2166.e9. [Content Brief]
- [2]. Xie Z, et al. Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia. Acta Pharm Sin B. 2023 Feb;13(2):739-753. [Content Brief]
- [3]. Zhu X, et al. Simultaneous determination of BGT-002 and its acyl glucuronide metabolite ZM326E-M2 in human plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2024 Jun 15;243:116056. [Content Brief]
